March 28th 2024
Mary-Ellen Taplin, MD, gives her advice on how to achieve work-life balance and make other career advancements in genitourinary cancer.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Hypofractionated Regimen Safe, Feasible in Elderly Bladder Cancer Patients
November 8th 2017In this interview we discuss results of the HYBRID trial, which tested a hypofractionated regimen of 36 Gy over six fractions in elderly muscle-invasive bladder cancer patients who were ineligible for standard treatments.
Insurance Type, Race Tied to Disparities in Prostate Cancer
November 7th 2017Men with Medicaid are more likely to present with metastatic prostate cancer than men presenting with prostate cancer who have private insurance, according to a new study. There are racial disparities in terms of prostate cancer outcomes among those privately insured, but not among Medicaid recipients.
Analysis Highlights Gaps in Cisplatin-Based Treatment for Advanced Urinary Tract Cancer
November 4th 2017An analysis of treatment patterns found that patients with advanced urinary tract cancer who are eligible for cisplatin-based chemotherapy fare better when they do receive such regimens than when they do not, highlighting the importance of following published treatment criteria.
CXCR4 Inhibitor Active in Clear Cell RCC
November 2nd 2017Combination treatment with a novel CXCR4 inhibitor and axitinib resulted in an encouraging overall response rate and disease control rate in patients with clear cell renal cell carcinoma, according to the results from phase I of a phase I/II trial.
CABOSUN Results Confirm Improved PFS With Cabozantinib for Advanced RCC
October 3rd 2017Cabozantinib reduced the risk for disease progression or death by 52% compared with sunitinib in patients with previously untreated advanced renal cell carcinoma, according to updated results from the CABOSUN trial.
Bevacizumab Plus TRC105 Failed to Improve PFS in Refractory, Metastatic RCC
September 13th 2017TRC105, a monoclonal antibody against endoglin, failed to improve progression-free survival when added to bevacizumab compared with bevacizumab alone in patients with refractory metastatic renal cell carcinoma.
Adding Ramucirumab Prolongs PFS in Urothelial Carcinoma
September 13th 2017The combination of ramucirumab and docetaxel prolonged progression-free survival over chemotherapy alone in patients with platinum-refractory advanced urothelial carcinoma, the first time in this setting that a regimen has improved outcomes over chemotherapy.
Extended Results Confirm Pembrolizumab Superiority in Recurrent Urothelial Carcinoma
September 12th 2017The advantage with pembrolizumab has continued to improve, offering significantly better overall survival than chemotherapy in patients with recurrent, advanced urothelial carcinoma, according to the mature results of a phase III trial.
Combination of TKI, Anti-PD1 Agent Active in Metastatic RCC
September 12th 2017More than half of patients with metastatic clear cell renal cell carcinoma treated with a combination of lenvatinib and pembrolizumab responded to treatment at week 24, according to interim results of a phase I/II study presented at the 2017 ESMO Congress.
Benefits Vary With Docetaxel and Abiraterone in High-Risk Prostate Cancer
September 11th 2017The first head-to-head comparison of docetaxel and abiraterone acetate for high-risk prostate cancer patients starting long-term hormone therapy found benefit with both treatments when added to ADT. Treatment decisions may come down to specific toxicities, which differ between the treatments.
Analysis: Major Prostate Cancer Screening Trials Agree on Mortality Reduction
September 7th 2017An analysis that corrected for differences in implementation found that the two main trials of prostate cancer screening in Europe and the United States both show a reduction in prostate cancer mortality with screening.
Surgery in Early Prostate Cancer Did Not Significantly Reduce Mortality
July 13th 2017Long-term follow-up found no significant differences in all-cause or disease-related mortality in men with early prostate cancer randomized to either radical prostatectomy or to observation. Surgery led to more adverse events, but less treatment for disease progression.